Brain

BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled

SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not been treated with carbidopa/levodopa...

Best Appetite Suppressants – Natural Over the Counter (OTC) Appetite Suppressant for Hunger Control & Fat Burner ( Men & Women) – By Phenq CrazyBulk in USA

CrazyBulk CrazyBulk Albany, New York, April 16, 2025 (GLOBE NEWSWIRE) -- Struggling to control your appetite and cravings? You're not...

AI, Neuromodulation & Thrombectomy Drive $7.6B Growth in U.S. Neurological Devices Market – New iData Research Report Forecasts $10B by 2030

VANCOUVER, BC, April 15, 2025 /PRNewswire/ - A new U.S. Neurological Devices Market Report provides essential insights for CEOs, CFOs, product...

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

– Clinically Meaningful Efficacy Observed on Multiple Assessments – – Confirmed Target Engagement with Reduced Iron Signal in MSA Affected...

error: Content is protected !!